Peptides > Adipotide (FTPP)
Adipotide (FTPP)
Adipotide (FTPP) Peptides , also known as FTPP, is an experimental weight loss treatment that kills fat cells by targeting the blood supply of those cells.
- Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
PEPTIDE INDEX
» Adipotide (FTPP)
» AICAR
» AOD9604
» ARA-290
» Bronchogen
» BPC-157
» B7-33
» Cardiogen
» Cartalax
» Cerebrolysin (215mg/ml, 10ml)
» Chonluten
» CJC-1295 DAC
» Cortagen
» DSIP
» Epithalon (Epitalon)
» Follistatin-315
» Follistatin-344
» FOXO4-DRI
» hGH Fragment 176-191
» GHK Basic
» GHK-Cu (Copper Peptide)
» GHRP-2
» GHRP-6
» GHRH (GH-Releasing Hormone)
» Glutathione
» Gonadorelin (GnRH)
» Hexarelin
» Humanin
» Ipamorelin
» Kisspeptin-10
» KPV (ACTH (11-13) alpha-MSH)
» Liraglutide (GLP-1 Analogue)
» Livagen
» LL-37 (CAP-18)
» Melanotan 2 (Melanotan II)
» MGF (C-terminal)
» MK-677 (Ibutamoren)
» ModGRF 1-29 (CJC-1295 No DAC)
» MOTS-c
» N-Acetyl Epithalon Amidate
» N-Acetyl Selank Amidate
» N-Acetyl Semax Amidate
» NAD+
» Ovagen
» Oxytocin
» Pancragen
» PE-22-28
» PEG-MGF (Pegylated MGF)
» Pinealon
» PNC-27
» Prostamax
» PT-141 (Bremelanotide)
» P21 (P021)
» Selank
» Semaglutide (GLP-1 Analogue)
» Semax
» Sermorelin
» SS-31
» TB-500 (Thymosin Beta-4)
» Tesamorelin
» Testagen
» Thymagen
» Thymosin Alpha-1
» Thyrotropin-TRH
» Tirzepatide
» Triptorelin
» Vesugen
» Vesilute
» Vilon
» VIP (Vasoactive Intestinal Peptide)
» GHK-Cu
» Retatrutide
Introduction to Adipotide
Adipotide, also known as FTPP or the proapoptotic peptide, is a promising new drug for weight loss and diabetes. It works by targeting and destroying fat cells, leaving the rest of the body unharmed. Studies on primates have shown that adipotide can cause significant weight loss, improve insulin sensitivity, and reduce some of the adverse effects of type 2 diabetes.
Molecular Structure of Adipotide
Sequence:Cysteine-Lysine-Glycine-Glycine-Arginine-Alanine-Lysine-Aspartate-Cysteine-Glycine-Glycine-(Lysine-Leucine-Alanine-Lysine-Leucine-Alanine-Lysine)2
Molecular Formula: C152H252N44O42
Molecular Weight: 2611.41 grams per mole
Research on Adipotide
Adipotide's Impact on Fat Loss
Adipotide, a groundbreaking new drug, entered phase I clinical trials in 2011 to test its ability to stop fat cells. Studies on rhesus monkeys showed that adipotide kills the blood vessels that feed white fat cells, causing them to die. This led to significant weight loss, a rapid reduction in body mass index (BMI), and improved insulin resistance.
Interestingly, Adipotide treatment not only caused weight loss, but it also changed monkeys’ eating habits. The monkeys that lost weight on Adipotide ate less food. This suggests that Adipotide may affect people’s food choices in a complex way.
The red data points show two different doses of adipotide. The graph highlights the significant impact of adipotide treatment on weight loss, showing a compelling difference in outcomes.
Graph B shows the effect of adipotide treatment on BMI compared to the control group. The blue line represents the BMI of the control group, and the red line represents the BMI of people who received adipotide treatment. The sharp drop in BMI in the treatment group demonstrates that adipotide effectively reduces BMI. This supports the idea that adipotide could be a valuable tool for managing weight and related health problems
Insulin Requirements Change (Area Under the Curve):
Chart A shows the change in insulin requirements for the treated group (red) and the control group (blue), as measured by the area under the curve (AUC). The AUC was calculated from the results of an IVGTT test. There is a noticeable contrast in insulin requirements between the two groups, with the red curve showing the impact of treatment. This graph highlights the significance of the therapy in changing insulin needs.
Insulinogenic Index Before and After Treatment:
Chart B shows the insulinogenic index of the treated group (red) and the control group (blue), before and after treatment. The data illustrates a striking decrease in insulin secretion within the treatment group post-treatment. This noteworthy decline in insulinogenic response highlights the transformative effects of the treatment on insulin regulation, suggesting potential benefits for individuals with insulin-related conditions.
Biscuit Consumption Variation:
Chart C shows how biscuit consumption changed in the treated and control groups, shown in red and blue, respectively. The contrasting trends in biscuit consumption are noteworthy. This data suggests that the treatment may have a noticeable impact on eating behavior, as evidenced by the different biscuit consumption patterns between the two groups.
Adipotide targets fat cells by interacting with the protein receptor prohibitin. This receptor is found on the surface of blood vessels that supply white fat tissue and cancer cells. Adipotide binds to prohibitin, which allows it to target these blood vessels and affect fat cells. This interaction with prohibitin is a key mechanism of adipotide’s unique action.
2. Adipotide and Cancer
Adipotide targets prohibitin, a molecule found in fat cells and linked to certain types of cancer. Cancer cells need a lot of blood to grow and spread quickly, and prohibitin helps them get it. The ability to selectively target prohibitin in cancer cells is a promising avenue for developing new therapies. These therapies could specifically target and affect cancer cells while minimizing harm to surrounding healthy tissues, potentially increasing the efficacy and precision of cancer treatments. This targeted approach has significant potential to improve outcomes and reduce side effects in the future.
3. Adipotide and Glucose Tolerance
Glucose tolerance refers to high blood sugar levels above the normal range. Diabetes is usually diagnosed with a blood test that checks your fasting glucose level or your glucose tolerance.
In the oral glucose tolerance test, you drink a predetermined quantity of sugar, and then your blood sugar levels are measured. Glucose tolerance is an indirect indicator of diabetes. An increase in glucose tolerance indicates a tendency to develop diabetes.
Elevated glucose levels can be managed through diet and exercise, but these methods require commitment and motivation. It is also important to realize that they often take a significant amount of time to produce noticeable results. People with impaired glucose tolerance often develop type 2 diabetes, which may require medication such as metformin or insulin.
However, research into adipotide has uncovered a compelling alternative.Adipotide, a peptide that rapidly improves glucose tolerance without affecting body weight, maybe a more effective treatment for glucose tolerance issues than traditional approaches.
Debates exist regarding whether adipotide directly induces fat loss or if it primarily reduces food intake, subsequently resulting in fat loss. It appears that adipotide indeed has a direct impact on fat loss. This hypothesis gains support from observations that the peptide induces alterations in fat cell density without necessarily causing a reduction in overall body weight. Additionally, it influences glucose tolerance independently of weight loss. These findings collectively suggest that adipotide’s effects on fat loss and glucose tolerance are not solely reliant on changes in body weight, emphasizing its potential as a direct agent for fat reduction and glucose tolerance improvement.
Managing elevated glucose levels can be achieved through dietary and exercise interventions, although these methods demand commitment and motivation. Furthermore, it’s important to recognize that they often require a significant amount of time to yield noticeable results. As a general trend, individuals with impaired glucose tolerance eventually progress to develop full-fledged type 2 diabetes, necessitating the use of medications such as metformin and, in certain instances, insulin.
However, research into adipotide has uncovered a compelling alternative. This peptide has demonstrated the ability to bring about rapid improvements in glucose tolerance that are not dependent on changes in body weight. This promising attribute suggests that adipotide may offer a more efficient and effective means of addressing glucose tolerance issues compared to traditional approaches.
Debates exist regarding whether adipotide directly induces fat loss or if it primarily reduces food intake, subsequently resulting in fat loss. It appears that adipotide indeed has a direct impact on fat loss. This hypothesis gains support from observations that the peptide induces alterations in fat cell density without necessarily causing a reduction in overall body weight. Additionally, it influences glucose tolerance independently of weight loss. These findings collectively suggest that adipotide’s effects on fat loss and glucose tolerance are not solely reliant on changes in body weight, emphasizing its potential as a direct agent for fat reduction and glucose tolerance improvement.
Future Prospects in Adipotide Research
Adipotide, a peptide that targets blood vessels, has been the subject of extensive research in two areas: fat loss and diabetes. This peptide is engineered to target specific cells within the blood vessels responsible for supplying fat tissue. Adipotide is an anti-angiogenic peptide that targets blood vessels, causing them to die. This leads to the death of the fat cells that the blood vessels were nourishing.
Anti-angiogenic molecules show promise as cancer treatments. Researchers are exploring the potential of adipotide, a promising therapeutic agent for cancer, fat loss, and diabetes.
Researchers have found that adipotide has few side effects and is well absorbed under the skin in mice, but it is not well absorbed orally. It is important to note that dosages used in mice may not be appropriate for humans. Peptide Sciences sells adipotide only for educational and scientific research purposes. It is not intended for human consumption.
To purchase Adipotide for research, follow all legal and ethical guidelines. You must be a licensed researcher or affiliated with an authorized institution. This ensures responsible use of Adipotide and compliance with regulations.
Article Author
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
This website provides information about in vitro products, which have only been tested in a laboratory. These products are not FDA-approved medicines or drugs and cannot be used on humans or animals.
